The agency says the proposal has the potential to significantly decrease disease and death from tobacco by "reducing youth experimentation and addiction."
A multistate outbreak of norovirus illnesses linked to raw oysters from Canada is under investigation in 13 states by the FDA.
The vaccines now in use are based on the form of the virus that circulated at the beginning of the pandemic and are less effective against the omicron variant. New options are in the works.
People who are 50 and older and certain immunocompromised individuals may get a second Pfizer-BioNTech or Moderna COVID-19 vaccine booster four months after they received the first.
No deaths were reported in tests, and there were no signs of myocarditis, or heart inflammation, as a side effect.
The FDA now cautions against using a specific lot of Abbott Nutrition's Similac PM 60/40 after a second infant dies. Abbott voluntarily recalled the specialty product on Monday.
Abbott Nutrition voluntarily recalled some powdered formulas sold under the Similac, Alimentum and EleCare brands. The FDA is investigating links to four bacterial infections, one of which was fatal.
"We believe additional information regarding the ongoing evaluation of a third dose should be considered as part of our decision-making for potential authorization," FDA officials said in a statement.
Now, both the Pfizer and the Moderna booster shots can be given five months after the second dose of vaccine — down from six months.
The Food and Drug Administration this week approved an injectable drug that helps prevent the spread of HIV. It only has to be taken once every eight weeks, compared to a daily oral pill.
In a highly anticipated decision, the Food and Drug Administration authorized Pfizer's Paxlovid as the first antiviral pill to treat COVID-19 at home.
Omicron has many more mutations than previous variants of concern, a fact that raises questions about how effective existing vaccines will be against the new form of the coronavirus.
The companies say a study of more than 10,000 volunteers showed a vaccine efficacy of 95% or greater for people receiving the booster.
A new Alzheimer's drug isn't reaching many patients. Doctors say reasons include its high cost, and lingering questions about its effectiveness.
Officials say the recall was prompted after a random sample tested positive for the organism listeria monocytogenes. No illnesses have been reported, the FDA says.